Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

euro adhoc: Sygnis Pharma AG
other
SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Receipt of mandatory offer
14.11.2008
Ad Hoc
Heidelberg, 14 November 2008 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN
DE0005043509; Prime Standard) has been informed today that dievini 
Hopp BioTech holding GmbH & Co. KG will make a compulsory bid to 
acquire all shares of SYGNIS Pharma AG at an appropriate price. The 
detailed conditions for the offer will be announced at a later date.
With the compulsory bid dievini Hopp BioTech holding GmbH & Co. KG 
also fulfils the relevant obligations of the other parties to which 
the voting rights of dievini Hopp BioTech holding GmbH & Co. KG have 
to be added. Accordingly, these parties will not make a separate 
offer.
This announcement has to be regarded in the light of SYGNIS Pharma's 
recent capital increase at the beginning of November in the course of
which dievini Hopp BioTech holding GmbH & Co. KG now owns voting 
rights of approx. 36%.
end of announcement                               euro adhoc

Further inquiry note:

Dr. Franz-Werner Haas
Vice President Operations
Telefon: +49(0)6221 454-812
E-Mail: franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG